📰 Clinical Development News
Page 78 - Clinical Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Development. Real-time updates on events, politics, business and more.
October 12, 2023
/PRNewswire/ -- The "Global Decentralized Clinical Trials Growth Opportunities" report has been added to ResearchAndMarkets.coms offering. The global...
October 12, 2023
NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell
October 11, 2023
The heavy burden on immediate family members with neurodegenerative diseases and their caregivers, was the initial driving force to study pharmacy for Andrea Pfeifer.
October 10, 2023
– Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous trials –– If approved by the FDA, RVO would be Vabysmo’s third indication in addition to wet age-related macular degeneration (AMD) and diabetic macular edema (DME) –– Vabysmo is the first and only treat...
October 10, 2023
The unique glutamatergic mechanism of action in Newron Pharmaceuticals’ investigational new drug can potentially produce a long-lasting antipsychotic response in patients with TRS and the benefits will accrue over time.
October 10, 2023
Complete clinical trials solution company, Hawthorne Effect, announced today (October 10) announced it had successfully recruited more than 1,000 patients in 48 states plus Hawaii for a study to qualify the prevalence of valvular heart disease (VHD).
October 9, 2023
Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Ce...
October 9, 2023
SCHLIEREN, Switzerland, October 09, 2023--LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorr
October 9, 2023
A 15-year partnership between Medidata, a Dassault Systèmes company, and the National Cancer Institute (NCI) has been extended by five years. The NCI is part of the National Institutes of Health.
October 9, 2023
Calliditas Therapeutics AB announced on Friday (October 5) that the European Medicines Agency (EMA) has issued a positive opinion on the company’s drug, setanaxib in Alport Syndrome (AS).